Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 193 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... August 26, 2021 Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... January 29, 2022 Load more HOT NEWS Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... Using Technology to Find Cancers Early and Exercise Improves Sexual Health... Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer How to Be Brave When Your Parent Has Cancer: A Kid’s...
